Diamyd to include children and accelerate patient recruitment in US Phase III study with the Diamyd® diabetes vaccine

Diamyd Medical reported today that from September 1, children from 10 years of age with type 1 diabetes will be included in the company’s US Phase III study of the Diamyd® diabetes vaccine. The company is also trebling the number of clinics and is investing in expanded recruitment activities in the US.Diamyd Medical’s Phase III study of the Diamyd® diabetes vaccine in the US has so far only been open to patients with type 1 diabetes aged between 16 and 20 years. From September 1, 2009, the study will also be open to children in the age range 10 to 15 years. Following the FDA’s decision in